SEngine Precision Medicine’s PARIS® Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR’s Molecular Cancer Therapeutics

NEXT STORY
FIRST STUDY OF HOMELESS ENCAMPMENTS FINDS LACK OF AFFORDABLE HOUSING TO BE KEY DRIVER
PREV STORY
Predictmedix and JUICEWORKS Form Strategic Partnership with CONNECTUS Global to Deploy Safe Entry Stations Nationwide
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EssilorLuxottica: First-half 2019 results – Combination at work and acceleration of the integration process – Strong free cash flow

author_avatar
NASDAQ Market News

Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair

LOS ANGELES, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) a biopharmaceutical ...

author_avatar
NASDAQ Market News

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

author_avatar
NASDAQ Market News